Citius Pharmaceuticals, Inc. Share Price

Equities

CTXR

US17322U2078

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 01/05/2024 BST 5-day change 1st Jan Change
0.7263 USD -2.68% Intraday chart for Citius Pharmaceuticals, Inc. +1.37% -3.99%
Sales 2024 * - Sales 2025 * 83.59M 6.69B Capitalization 135M 10.78B
Net income 2024 * -36M -2.88B Net income 2025 * 5M 400M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.61 x
P/E ratio 2024 *
-3.39 x
P/E ratio 2025 *
49.8 x
Employees 22
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.18%
More Fundamentals * Assessed data
Dynamic Chart
Citius Pharmaceuticals Launches $15 Million Offering MT
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma CI
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Citius Pharmaceuticals Resubmits Application for Lymphoma Treatment MT
Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir CI
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited DJ
Citius Pharmaceuticals Completes Enrollment in Phase 3 Trial for Mino-Lok MT
Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight DJ
Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR? in Combination with Checkpoint Inhibitor CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
More news
1 day+7.85%
1 week-2.74%
1 month-16.83%
3 months+20.18%
6 months-0.84%
Current year-1.35%
More quotes
1 week
0.64
Extreme 0.64
0.77
1 month
0.64
Extreme 0.64
1.07
Current year
0.60
Extreme 0.6
1.07
1 year
0.60
Extreme 0.6
1.56
3 years
0.60
Extreme 0.6
4.56
5 years
0.40
Extreme 0.4
4.56
10 years
0.40
Extreme 0.4
37.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 79 30/06/13
Director of Finance/CFO 57 26/11/17
Chief Tech/Sci/R&D Officer - 31/12/21
Members of the board TitleAgeSince
Director/Board Member 77 30/09/15
Director/Board Member 67 06/02/23
Chief Executive Officer 79 30/06/13
More insiders
Date Price Change Volume
01/05/24 0.7263 -2.68% 537 567
30/04/24 0.7463 +7.85% 983,919
29/04/24 0.692 +4.09% 842,594
26/04/24 0.6648 -9.25% 2,776,465
25/04/24 0.7326 +2.25% 586,758

Delayed Quote Nasdaq, April 30, 2024 at 09:00 pm

More quotes
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.7463 USD
Average target price
4 USD
Spread / Average Target
+435.98%
Consensus